PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.\', \'Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.\', \'Human Immunodeficiency Virus Lab, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.\', \'Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.\', \'The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1093/jnci/djab174
?:doi
?:hasPublicationType
?:journal
  • Journal of the National Cancer Institute
is ?:pmid of
?:pmid
?:pmid
  • 34453830
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 5.488
?:rankingScore_hIndex
  • 326
?:title
  • Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all